Accès ouvert
2010
article
OpenAlex
Munemasa Ryu, Masaaki Hamano, Akira Nakagawara, Masayuki Shinoda et autres
Most clinical pathways in treating cancers in Japan are based on individual physician's personal experiences rather than on an empirical analysis of clinical data such as benchmark comparison with other hospitals. Therefore, these pathways are far from being standardized. By comparing detailed …
jp
(code pays fourni par la source)
2010
article
OpenAlex
Nobuhiro Takiguchi, Matsuo Nagata, Hiroaki Soda, Yukihiro Nomura et autres
jp
(code pays fourni par la source)
2010
conference-abstract
OpenAlex
J. Kim, Yongzhe Hong, J. Lee, Munemasa Ryu et autres
3579 Background: Colorectal cancer with deficient mismatch repair system (dMMR) has been associated with favorable prognosis in early-stage disease. The influence of dMMR on response to chemotherapy in metastatic colorectal cancer (mCRC) has not been fully defined yet. The aim of our …
2010
conference-abstract
OpenAlex
Baek‐Yeol Ryoo, Do Hyun Yoon, Munemasa Ryu, Soobin S. Lee et autres
e14669 Background: Sorafenib is the only drug that has shown a survival benefit in patients with hepatocellular carcinoma (HCC) in randomized phase III trials. The efficacy and safety of sorafenib in the treatment of recurrent HCC after liver transplantation, however, has not …
2009
conference-abstract
OpenAlex
Do Hyun Yoon, H.J. Lee, S.S. Lee, J.R. Lee et autres
2009
conference-abstract
OpenAlex
Mohleen Kang, Munemasa Ryu, Baek‐Yeol Ryoo, C. Kim et autres
2009
article
OpenAlex
Rajesh Kumar Gupta, Akinari Miyazaki, Akihiro Cho, Munemasa Ryu
in, jp
(code pays fourni par la source)
2009
book-chapter
OpenAlex
Munemasa Ryu
2009
book-chapter
OpenAlex
Munemasa Ryu
2009
book-chapter
OpenAlex
Munemasa Ryu
2009
book-chapter
OpenAlex
Munemasa Ryu
2009
book-chapter
OpenAlex
Munemasa Ryu